Ivan Efremov is a Senior Director, Head of Medicinal Chemistry at Fulcrum Therapeutics. He started his medicinal chemistry career in 2001 when he joined Pfizer after obtaining his PhD with Professor Leo Paquette at The Ohio State University. While at Pfizer, he significantly contributed to multiple projects including delivery of development candidates for CNS, immunology and rare disease indications. He joined Fulcrum Therapeutics in 2017 where he led a chemistry effort culminating in nomination of a development candidate for sickle cell disease. His research interests include structure-based design, fragment-based lead generation, and chemogenomics. He is an author on more than 50 publications and patents.